Biogen's galiximab enters Ph III cancer trial
US drugmaker Biogen Idec says it has begun a Phase III trial of an investigational anti-CD80 monoclonal antibody, named galiximab, for the treatment of lymphoma. The company explained that the study will compare the agent in combination with Rituxan (rituximab), against Rituxan plus placebo in patients suffering from relapsed or non-responsive, follicular non-Hodgkin's lymphoma.
Biogen said that, because the CD80 molecule is found uniformly on Reed-Sternberg cells which form the malignant component of both Hodgkin's and non-Hodgkin's lymphomas, it is a suitable target for further proof-of-principal assessments.
The firm went on to say that the program was being conducted under the Food and Drug Administration's special protocol assessment criteria, which was issued in July last year. The study will seek to enroll 700 patients at more than 150 centers worldwide.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze